Stock info Biotest | Filter  Basic-Info

Biotest

The past year was a good investment year for Biotest investors

Over the last 12 months (from December 2015 till December 2016), that were loss-making period for the investors in Biotest, the stock lost around 16 percent. The period between August 2011 and August 2016 was a loss-making period for the investors. The stock lost on average 3 percent. Biotest's revenues between 2011 and 2015 were very volatile through the time and moved between 439,97 million euros and 589,6 million euros. Biotest's net incomes between 2011 and 2015 were very volatile and moved between 18,73 million euros and -82,5 million euros.

Biotest has it' headquarter based in Dreieich. The company mostly operates in the biotech sector. Dr.Gregor Schulz is operating by ' CEO. The CFO of the company is Michael Ramroth. The global biotech companies gained around 59 percent over the last 10 years. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

Over the past 5 years the German company paid out dividends. On average Biotest's dividend yield over the past 5 years was around 0,73 percent annually.

Biotest' balance mostly consists of equity

At the end of 2015 the biotech company's balance sheet equaled 962,7 million euros. The total debt was around 550,5 million euros. This is 57,18 percent of the total balance sheet. At the end of 2015 the biotech company's stock was traded with a price/earnings-ratio -29. So the stock' value was -29 times the 2015' earnings per share. Based on the classical stock valuation theories the German stock can be seen as a growth stock.

At the end of 2015 the biotech company's market size (her number of outstanding share times the stock price) equaled around 582,49 million euros. At the end of 2015 the German company had around 39,57 million stocks listed.

All Biotest's financial reports are available here. More information about Biotest can be found it's website. .